TY - JOUR
T1 - Development and Optimization of Hybrid Polymeric Nanoparticles of Apigenin
T2 - Physicochemical Characterization, Antioxidant Activity and Cytotoxicity Evaluation
AU - Zafar, Ameeduzzafar
AU - Alruwaili, Nabil K.
AU - Imam, Syed Sarim
AU - Alsaidan, Omar Awad
AU - Ahmed, Mohammed Muqtader
AU - Yasir, Mohd
AU - Warsi, Musarrat Husain
AU - Alquraini, Ali
AU - Ghoneim, Mohammed M.
AU - Alshehri, Sultan
N1 - Publisher Copyright:
© 2022 by the authors. Li-censee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Breast cancer is the most common cancer in females and ranked second after skin cancer. The use of natural compounds is a good alternative for the treatment of breast cancer with less toxicity than synthetic drugs. The aim of the present study is to develop and characterize hybrid Apigenin (AN) Nanoparticles (NPs) for oral delivery (AN-NPs). The hybrid AN-NPs were prepared by the self-assembly method using lecithin, chitosan and TPGS. Further, the NPs were optimized by Box-Behnken design (3-factor, 3-level). The hybrid NPs were evaluated for particle size (PS), entrapment efficiency (EE), zeta potential (ZP), and drug release. The optimized hybrid NPs (ON2), were further evaluated for solid state characterization, permeation, antioxidant, cytotoxicity and antimicrobial study. The formulation (ON2) exhibited small PS of 192.6 ± 4.2 nm, high EE 69.35 ± 1.1%, zeta potential of +36.54 mV, and sustained drug release (61.5 ± 2.5% in 24 h), as well as significantly (p < 0.05) enhanced drug permeation and antioxidant activity. The IC50 of pure AN was found to be significantly (p < 0.05) lower than the formulation (ON2). It also showed significantly greater (p < 0.05) antibacterial activity than pure AN against Bacillus subtilis and Salmonella typhimurium. From these findings, it revealed that a hybrid AN polymeric nanoparticle is a good carrier for the treatment of breast cancer.
AB - Breast cancer is the most common cancer in females and ranked second after skin cancer. The use of natural compounds is a good alternative for the treatment of breast cancer with less toxicity than synthetic drugs. The aim of the present study is to develop and characterize hybrid Apigenin (AN) Nanoparticles (NPs) for oral delivery (AN-NPs). The hybrid AN-NPs were prepared by the self-assembly method using lecithin, chitosan and TPGS. Further, the NPs were optimized by Box-Behnken design (3-factor, 3-level). The hybrid NPs were evaluated for particle size (PS), entrapment efficiency (EE), zeta potential (ZP), and drug release. The optimized hybrid NPs (ON2), were further evaluated for solid state characterization, permeation, antioxidant, cytotoxicity and antimicrobial study. The formulation (ON2) exhibited small PS of 192.6 ± 4.2 nm, high EE 69.35 ± 1.1%, zeta potential of +36.54 mV, and sustained drug release (61.5 ± 2.5% in 24 h), as well as significantly (p < 0.05) enhanced drug permeation and antioxidant activity. The IC50 of pure AN was found to be significantly (p < 0.05) lower than the formulation (ON2). It also showed significantly greater (p < 0.05) antibacterial activity than pure AN against Bacillus subtilis and Salmonella typhimurium. From these findings, it revealed that a hybrid AN polymeric nanoparticle is a good carrier for the treatment of breast cancer.
KW - Antimicrobial activity
KW - Apigenin
KW - Breast cancer
KW - Cytotoxic activity
KW - Hybrid nanoparticle
UR - http://www.scopus.com/inward/record.url?scp=85124234454&partnerID=8YFLogxK
U2 - 10.3390/s22041364
DO - 10.3390/s22041364
M3 - Article
C2 - 35214260
AN - SCOPUS:85124234454
SN - 1424-8220
VL - 22
JO - Sensors
JF - Sensors
IS - 4
M1 - 1364
ER -